United States-based RXi Pharmaceuticals has collaborated with United States-based Iovance Biotherapeutics.

It was reported yesterday that the collaboration is aimed at assessing RXi's sd-rxRNA therapeutic compounds with Iovance's autologous cell therapy based on tumour-infiltrating lymphocytes (TILs) for use in the treatment of cancer.

RXi Pharmaceuticals president and CEO, Geert Cauwenbergh, said, 'Iovance is the leading company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. Our agreement will allow Iovance to explore their proprietary TIL technology and our proprietary sd-rxRNA technology. Under this research collaboration, we will further investigate and expand the recently published data with TIL and sd-rxRNA products, which demonstrated potentially enhanced tumour killing activity of TIL.'